AbbVie entered the second quarter of 2025 in very strong shape. The company has shown that its strategy of focusing on a diversified portfolio of drugs is bearing fruit and that it can counter the impact of the gradual decline in Humira revenues. New drugs in immunology and neurosciences played a major role in the growth, which are becoming new pillars of the overall business. At the same time, the company stressed that it continues to invest in research, acquisitions and clinical trials, building a foundation for sustainable growth in the years ahead.

Investors could appreciate that AbbVie $ABBV not only built on the solid results of previous periods, but also raised its full-year outlook. This demonstrates management's strong confidence in future developments and ability to offset losses on legacy products. The overall results thus send a clear signal that the transition from one dominant brand to a broader portfolio is on track.

How was the last quarter?

In the second quarter, AbbVie…